EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.
Shaofang WuFeng GaoSiyuan ZhengChen ZhangEmmanuel Martinez-LedesmaRavesanker EzhilarasanJie DingXiaolong LiNingping FengAsha MultaniErik P SulmanRoel G VerhaakJohn F de GrootTimothy P HeffernanW K Alfred YungDimpy KoulPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
EGFR-amplified cells are highly sensitive to talazoparib. Our data provide insight into the potential of using EGFR amplification as a selection biomarker for the development of personalized therapy.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- dna damage response
- tyrosine kinase
- dna repair
- induced apoptosis
- nucleic acid
- dna damage
- big data
- electronic health record
- fluorescent probe
- signaling pathway
- risk assessment
- endoplasmic reticulum stress
- mesenchymal stem cells
- deep learning
- machine learning
- cell death
- bone marrow
- climate change
- human health
- high resolution
- artificial intelligence
- smoking cessation